Massive Bio to Present SYNERGY-AI Trial-in-Progress Poster Presentation at Upcoming AACR 2019 using its AI Clinical Trial Matching Technology, and Announces Strategic Partnership in Precision Oncology with US-Based Admera Health
NEW YORK, April 02, 2019 (GLOBE NEWSWIRE) -- Massive Bio, Inc., a leader in providing simplified and affordable access to clinical trials and precision oncology to cancer patients treated at community-based oncology practices, announced today that its Trials-in-Progress poster titled “SYNERGY-AI: Artificial intelligence based precision oncology clinical trial matching and [...]
Chinese-Based MedCDx and US-Based Admera Health Enter into Strategic Partnership to Co-develop Companion Diagnostics
South Plainfield, NJ-February 26, 2019 – Today, MedCDx and Admera Health announced a non-exclusive collaborative agreement. Under the terms of the agreement, MedCDx (formerly Qiagen Suzhou Translational Medicine) and Admera Health will gain access to each other’s existing portfolios and co-develop new technologies, specifically companion diagnostics. MedCDx has an [...]
Admera Health Genetic Tests are Now In-Network with CareFirst BlueCross BlueShield, Maryland, Washington D.C, and Northern Virginia
SOUTH PLAINFIELD, NJ, December 11, 2018 - Admera Health (www.admerahealth.com), an advanced molecular diagnostics company, announced today that its genetic testing services are now available as in-network benefits under CareFirst Blue Cross Blue Shield. With over 3.2 million members, CareFirst offers the widest coverage and the largest network for [...]
Admera Health Adds Clinical Genomics Expert, Dr. Ruben Bonilla-Guerrero, to Management Team
South Plainfield, NJ – December 04 2018 – Admera Health, a molecular diagnostic company, welcomes Dr. Ruben Bonilla-Guerrero as Medical Director to the company. Ruben Bonilla-Guerrero obtained his M.D. from the Universidad Veracruzana in Mexico followed by 14 years working experience at Mayo Clinic in Minnesota, including fellowships in [...]
Admera Health Expands Liquid Biopsy Offering to Include Detection of Copy Number Variation and Microsatellite Instability
South Plainfield, NJ – October 23, 2018 - At CAP18, in Chicago, IL, Admera Health (www.admerahealth.com), unveiled an expansion to its next generation sequencing (NGS) based LiquidGx™ test for solid tumor-targeted therapy selection from a blood sample. This extended version increases the utility of the assay by raising the [...]